title: Prostate cancer risk assessment program: a 10-year update of cancer detection.
abstract: OBJECTIVE
  Guidelines for screening men at high risk for prostate cancer remain under investigation. We report our 10-year cancer detection data from the Prostate Cancer Risk Assessment Program, a longitudinal screening program for men at high risk.
  
  
  METHODS
  Men between ages 35 and 69 years with a family history of prostate cancer, any black man regardless of family history or any patient with a known mutation in the BRCA 1 gene are eligible for the Prostate Cancer Risk Assessment Program and undergo longitudinal followup. Cancer detection, prostate cancer features and the predictive value of screening parameters were determined based on Prostate Cancer Risk Assessment Program biopsy criteria.
  
  
  RESULTS
  A total of 609 men were accrued to the Prostate Cancer Risk Assessment Program as of the end of June 2006, of whom 61.2% were black. Of all participants 19% underwent prostate biopsies. The prostate cancer incidence was 9.0%, more than 90% of prostate cancers were Gleason score 6 or higher and 22% were Gleason score 7 or higher. The majority were organ confined. Of men diagnosed with prostate cancer 20% had a prostate specific antigen of less than 2.5 ng/ml and a free prostate specific antigen of less than 25% with a normal digital rectal examination.
  
  
  CONCLUSIONS
  Our results support aggressive screening measures for men at high risk for prostate cancer. The majority of cancers detected were at a prostate specific antigen of less than 4.0 ng/ml with a fifth diagnosed at a prostate specific antigen of below 2.5 ng/ml. These cancers were intermediate to high grade and organ confined, indicating a greater likelihood of cure following local therapy in these men.
authors.affiliation: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19012, USA. Veda.Giri@fccc.edu
authors.forename: Veda N
authors.initials: VN
authors.lastname: Giri
authors.forename: Jennifer
authors.initials: J
authors.lastname: Beebe-Dimmer
authors.forename: Mark
authors.initials: M
authors.lastname: Buyyounouski
authors.forename: Andre
authors.initials: A
authors.lastname: Konski
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Feigenberg
authors.forename: Robert G
authors.initials: RG
authors.lastname: Uzzo
authors.forename: Gerald
authors.initials: G
authors.lastname: Hanks
authors.forename: Andrew K
authors.initials: AK
authors.lastname: Godwin
authors.forename: David Y T
authors.initials: DY
authors.lastname: Chen
authors.forename: Robert
authors.initials: R
authors.lastname: Gordon
authors.forename: Terrence
authors.initials: T
authors.lastname: Cescon
authors.forename: Susan
authors.initials: S
authors.lastname: Raysor
authors.forename: Deborah
authors.initials: D
authors.lastname: Watkins-Bruner
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood; D001706:Biopsy; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening / Q000639:trends*; D008875:Middle Aged; D010414:Pennsylvania / Q000453:epidemiology; D015397:Program Evaluation; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology; D012189:Retrospective Studies; D018570:Risk Assessment; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen